SAN DIEGO, November 1, 2022 – Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that management will present at the following investor conferences during November 2022:
- Guggenheim 4th Annual Immunology and Neurology Day, November 14-15, in New York, NY
- Stifel Healthcare Conference, November 15-16, in New York, NY
About Pipeline Therapeutics
Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. Its flagship program, PIPE-307, has completed two Phase 1 clinical trials – a SAD/MAD study and a PET study – in healthy volunteers, and has received Investigational New Drug clearance from the Food and Drug Administration to initiate clinical development in relapsing-remitting MS patients.
For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.
Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com
Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com
